Peptide Microarray Market Size, Share & Trends Analysis Report By Application (Disease Diagnostics, Protein Functional Analysis), By Type (Instruments, Services), By End-user, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global peptide microarray market size was valued at USD 793.4 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 4.51% from 2023 to 2030. Peptide microarrays are a robust technique in the field of proteomics & clinical assays that can track the binding activity, histone-modifying enzymes, and protein linkage function on a large scale. The growing cancer burden and advanced technology are the primary factors boosting the industry's growth globally. Furthermore, the increased incidence of chronic diseases will also support global industry growth. As per the International Diabetes Federation’s Diabetes Atlas Tenth Edition 2021, globally, around 537 million adults were diagnosed with diabetes in 2021.

This number is projected to increase to 643 million by 2030 & 783 million by 2045. Furthermore, the increased need for molecular-based diagnostics approaches combined with advancements in diagnostic testing technologies dominate the industry. In February 2020, the U.S. Food & Drug Administration changed the definition of a biologic to be included in synthetic peptides and chemically synthesized polypeptides with a sequence of at least 40 amino acids but no more than 100 amino acids (synthetic proteins). As a result, the aforementioned factors are projected to boost industry growth in the coming years.

However, reimbursement challenges are projected to stymie industry expansion. The development of treatments necessitates a thorough understanding of the role of COVID-19 in the SARS-CoV-2 infection process. The discipline of proteomics is well-equipped with the techniques needed to meet this challenge. For instance, in October 2020, researchers emphasized in an article published in the Journal of Proteins & Proteomics, that advances in proteome technology will not only expedite efforts in combating the coronavirus pandemic but will also help to address the current COVID-19 situation.

With an increase in the number of chronic diseases, there has been a surge in the requirement for molecular diagnostic tools in recent years. Furthermore, peptide microarray diagnostic tools are inexpensive, which drives industry growth. In January 2020, a firm named PEPperPRINT introduced the proteome-wide peptide microarray, which incorporates the COVID-19 2019-nCoV coronavirus. It is utilized to detect and localize IgG and IgM Abs in patient serum. This is done for vaccine production diagnostic tests. It is one of the factors driving market acceleration, thus propelling industry growth.

Type Insights

On the basis of types, the global industry has been further categorized into services, instruments, and reagents. The services type segment is expected to register the fastest growth rate of more than 4.87% between 2023 and 2030. Several specialized companies offer microarray service solutions. Outsourcing this application may save time and effort while also providing access to technical skills and facilities specialized to diversify microarray-based research. These services can provide researchers with the benefits of tailored screening of a large number of distinct targets and markers.

Hence, it is expected to increase the demand for peptide microarray and further boost the growth of the segment. The instruments segment held a considerable share in 2022 owing to technically advanced peptide microarray products and several forms of study in chronic illnesses, such as cancer, autoimmune & infectious diseases. PEPperPRINT, for example, provides PEPperCHIP Standard Peptide Microarrays, which encompass epitopes, antigens, and viral proteomics and are widely used in a variety of studies (allergen, cancer, and signature discovery).

Application Insights

The disease diagnostics segment led the industry in 2022 and accounted for the maximum share of more than 54.95% of the overall revenue. The rising complexity of chronic diseases is projected to increase the demand for early disease diagnosis in hospitals, consequently expanding the use of diagnostics capacities, which is projected to increase the use of peptide microarrays. According to the American Cancer Society, the anticipated prevalence of new cancer cases in 2022 was 1.9 million, with 609,360 deaths attributable to cancer in the U.S. Breast, lung, prostate, and colon cancer were the most frequent cancers in the U.S.

These factors are expected to assist the segment to maintain its dominance in the industry. However, antibody characterization is anticipated to witness the fastest growth rate from 2023 to 2030. Characterization of antibodies occurs both upstream and downstream in the development of new drugs and biosimilars. Characterization studies are vital during the early development of drugs to screen the correct mAb molecule by specifying the critical qualitative parameters. It can also be used to determine antibody type, epitope specificity, binding kinetics, cross-reactivity, and antibody affinity, hence propelling segment growth.

End-user Insights

The pharmaceutical and biotechnology companies segment led the industry in 2022 and accounted for the largest share of more than 56.00% of the total revenue. The segment is estimated to expand further at a significant growth rate from 2023 to 2030. Many major firms are investing in R&D to provide products and services for the early detection and management of chronic diseases. As a result, organizations are embracing improved microarray technologies, propelling the worldwide microarray market.

Nimble Medicines, a biotechnology business involved in the discovery & production of peptide therapeutics, announced in September 2021 that their strategic research agreement with Incyte has been extended to include the development of further innovative peptide therapeutics. In November 2020, PEPperPRINT announced a collaboration with Lucerna-Chem. Customers in Switzerland could now access PEPperCHIP Peptide Microarray products & PEPperMAP Services via Lucerna-Chem thanks to a new distribution arrangement. As a result, such agreements are projected to boost market growth in the region by offering advanced instruments.

Regional Insights

The North American region dominated the global industry in 2022 and accounted for the largest share of more than 48.00% of the overall revenue. The large share of the region can be primarily attributed to its improved healthcare facilities, as well as increased R&D spending. There is also awareness among healthcare personnel and the general public about the early detection and treatment of chronic diseases, which increases diagnostic accuracy. A majority of the industry's leading competitors are headquartered in North America, which further propels market expansion.

On the other hand, the Asia Pacific region is expected to register the fastest growth rate during the forecast period due to increased government support in the healthcare industry, high awareness about antibody-based research, and expansion of proteomics in the region. The chronic disease prevalence has increased in Indonesia, and the rising demand for fast & precise diagnosis can be achieved by microarrays, which will drive market expansion in the Asia Pacific region even further.

Key Companies & Market Share Insights

The continuous demand for peptide microarray solutions by multiple end-users has created numerous growth opportunities for industry players. For instance, in June 2022, Ariceum Therapeutics introduced EUR 25M Series A to enhance its lead asset, Satoreotide, for the diagnosis of low- as well as high-neuroendocrine cancers. Some of the key players in the global peptide microarray market include:

• PEPperPRINT GmbH

• RayBiotech Life, Inc.

• Creative Biolabs

• Aurora Instruments Ltd.

• Kinexus Bioinformatics Corp.

• Bio-Synthesis

• Microarrays Inc.

• Bio-Rad Laboratories

• JPT Peptide Technologies

• Merck KGaA

• Innopsys

Peptide Microarray Market Report Scope

Global Peptide Microarray Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global peptide microarray market report on the basis of type, application, end-user, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Instruments

  • Reagents

  • Services

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Disease Diagnostics

  • Protein Functional Analysis

  • Antibody Characterization

  • Drug discovery

• End-user Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical & Biotechnology Companies

  • Hospitals & Clinics

  • Diagnostic Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait